The Manufacturers Life Insurance Company Takes $467,000 Position in Azenta, Inc. $AZTA

The Manufacturers Life Insurance Company purchased a new position in Azenta, Inc. (NASDAQ:AZTA) in the 2nd quarter, HoldingsChannel.com reports. The fund purchased 18,280 shares of the company’s stock, valued at approximately $467,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in AZTA. BlackRock Inc. acquired a new stake in shares of Azenta in the second quarter valued at about $192,152,000. Conestoga Capital Advisors LLC raised its position in shares of Azenta by 116.1% during the 1st quarter. Conestoga Capital Advisors LLC now owns 2,844,546 shares of the company’s stock worth $60,105,000 after purchasing an additional 1,528,145 shares during the last quarter. Front Street Capital Management Inc. acquired a new position in shares of Azenta during the 2nd quarter worth about $33,212,000. Millennium Management LLC lifted its stake in Azenta by 41.6% in the 3rd quarter. Millennium Management LLC now owns 1,698,562 shares of the company’s stock valued at $48,783,000 after buying an additional 499,216 shares in the last quarter. Finally, Scopia Capital Management LP acquired a new stake in Azenta in the 3rd quarter worth about $14,026,000. 99.08% of the stock is owned by hedge funds and other institutional investors.

Azenta Stock Performance

NASDAQ:AZTA opened at $31.33 on Monday. Azenta, Inc. has a one year low of $15.93 and a one year high of $41.73. The stock has a market cap of $1.37 billion, a PE ratio of -11.35 and a beta of 1.39. The stock has a 50 day moving average price of $29.73 and a 200 day moving average price of $25.25.

Azenta (NASDAQ:AZTA) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.16 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.05. The company had revenue of $161.18 million for the quarter, compared to analyst estimates of $149.31 million. Azenta had a positive return on equity of 1.18% and a negative net margin of 20.63%.

Analyst Ratings Changes

AZTA has been the subject of several research reports. Weiss Ratings upgraded Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 26th. Needham & Company LLC boosted their price target on Azenta from $33.00 to $37.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $41.20.

Azenta Company Profile

Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.